Samil Pharmaceutical announced on May 22 that it has signed a memorandum of understanding (MOU) with U.S.-based ophthalmic specialty company KC Pharmaceuticals to cooperate on expansion into the North American market.
Founded in 1987 and headquartered in Pomona, California, KC Pharmaceuticals specializes in ophthalmic solutions and contact lens care products. The company is recognized as one of the largest private-label ophthalmic product manufacturers in North America.
Its major customers include leading U.S. retailers and pharmacy chains such as , , , , and . KC Pharmaceuticals supplies a variety of ophthalmic products including dry eye treatments, artificial tears, redness relievers, and allergy eye drops.
Under the agreement, Samil Pharmaceutical and KC Pharmaceuticals will first discuss the distribution of Samil’s “Eyetoo Mini” eye drops in the North American market.
The two companies also plan to jointly explore broader business opportunities in North America, including product supply, local commercialization, distribution partnerships, and business development initiatives.
Samil Pharmaceutical said it is accelerating efforts to obtain U.S. FDA current Good Manufacturing Practice (cGMP) certification to support its North American expansion strategy.
In particular, both companies agreed to cooperate on long-term strategic initiatives leveraging their regional networks and business infrastructure in North America. The collaboration is expected to include market expansion strategies, business development cooperation, and the establishment of local commercialization platforms.

















